Drugs News and Research

RSS

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

Dense surrounding tissue can block drugs from reaching pancreatic cancer tumors, but it can also help prevent the cancer from spreading. Now a new study by UNC Lineberger Comprehensive Cancer Center researchers and collaborators helps explain the conflicting role of the surrounding tissue known as stroma. In the study, the researchers revealed that based on molecular characteristics, there are two subtypes of pancreatic cancer stroma.

9 Sep 2015

Scientists identify new drug target to treat heart arrhythmias

Scientists at The Ohio State University Davis Heart and Lung Research Institute have identified a new target they hope will help make the next drug discovery for patients suffering from heart arrhythmias happen sooner.

9 Sep 2015

Researchers use stem cell-derived 'mini-brains' to identify drug candidate for rare neurological disorder

Using "mini-brains" built with induced pluripotent stem cells derived from patients with a rare, but devastating, neurological disorder, researchers at University of California, San Diego School of Medicine say they have identified a drug candidate that appears to "rescue" dysfunctional cells by suppressing a critical genetic alteration.

9 Sep 2015

Gallup-Palmer report: 57% of U.S. adults use chiropractic care for back or neck pain

According to a new Gallup-Palmer report that tested public assumptions about chiropractic care, 57 percent of U.S. adults are likely to visit a doctor of chiropractic (DC) if they experience back or neck pain.

9 Sep 2015

UCSF researchers lead $10 million research project on pediatric cancer

Researchers at UC San Francisco are leading a five-year, $10 million research project dedicated to pediatric cancer, funded by the first grant of its kind to focus on a molecular pathway that underlies many cancers rather than on a cancer in a particular organ or tissue in the body.

9 Sep 2015

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research.

9 Sep 2015

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

Children's Cancer Institute welcomes its inclusion, by the US National Cancer Institute (NCI), in a systematic program of drug evaluation in childhood cancer.

9 Sep 2015

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

Researchers at Southern Methodist University, Dallas, have discovered three new drug-like compounds that could ultimately offer better odds of survival to prostate cancer patients.

9 Sep 2015

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

The Children's Hospital at Montefiore and the NCI-designated Albert Einstein Cancer Center today announced receipt of $1.3 million grant from the National Cancer Institute, part of the National Institutes of Health.

9 Sep 2015

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Inside our bones there is fat. Diabetes increases the amount of this marrow fat. And now a study from the UNC School of Medicine shows how some diabetes drugs substantially increase bone fat and thus the risk of bone fractures.

9 Sep 2015

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.

9 Sep 2015

DNDi unveils plans to better respond to the needs of neglected patients

After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.

9 Sep 2015

Researchers identify new way to help AML patients avoid a relapse

A protein domain once considered of little importance may be key to helping patients who are fighting acute myeloid leukemia (AML) avoid a relapse.

8 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.

8 Sep 2015

Why do we sleep? An interview with Professor Wisden

It is true that we still do not know why we need to sleep every night. Sleep is essential for health. We have to do it every day. But nobody yet knows why. This fact amazes me.

8 Sep 2015

Lund University researchers reveal how the body develops acute pancreatitis

Researchers at Lund University in Sweden may have discovered one of the keys to understanding how the body develops acute pancreatitis. The results offer hope for the development of drugs that specifically target the disease.

8 Sep 2015

Drugs News and Research

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

Scientists identify new drug target to treat heart arrhythmias

Researchers use stem cell-derived 'mini-brains' to identify drug candidate for rare neurological disorder

Gallup-Palmer report: 57% of U.S. adults use chiropractic care for back or neck pain

UCSF researchers lead $10 million research project on pediatric cancer

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

DNDi unveils plans to better respond to the needs of neglected patients

Researchers identify new way to help AML patients avoid a relapse

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

Why do we sleep? An interview with Professor Wisden

Lund University researchers reveal how the body develops acute pancreatitis

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News